ArticleBioactive materials2027
Ultrasound-responsive nanotherapy promotes axonal regeneration after SCI via reactivating CREB/miR-129-5p signaling.
Article in Bioactive materials, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spinal cord injury (SCI) remains a devastating neurological disorder with few effective therapeutic interventions due to the poor intrinsic regenerative capacity of adult central nervous system neurons. Here, we identified miR-129-5p as a downstream effector of cAMP-response element binding protein (CREB) signaling that promotes axonal growth by suppressing glycogen synthase kinase-3β (GSK3β). Leveraging this regenerative mechanism, we developed a low-intensity focused ultrasound (LIFU)-responsive biomimetic nanoplatform (CM-miR-CNP@PFP) for targeted SCI therapy. The platform comprises miR-129-5p/perfluoropentane (PFP)-loaded cationic lipid nanoparticles (CNPs) coated with hybrid membranes from RVG-engineered human umbilical cord mesenchymal stem cells and macrophages. The biomimetic coating grants superior immune evasion, prolonged circulation, and precise neuronal targeting. Under local LIFU irradiation, CM-miR-CNP@PFP undergoes acoustic droplet vaporization (ADV), a liquid-to-gas phase transition that enhances lesion-site accumulation and cellular delivery of miR-129-5p. In vivo, this ultrasound-responsive therapy significantly attenuated astroglial and fibrotic scar-associated changes, promoted axonal regeneration, and improved motor function. Overall, this biomimetic nanoplatform represents a promising strategy for targeted miRNA delivery and neural regeneration after SCI, with potential for further translational development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.